I’m only seeing this, when you don’t use the reply I don’t get a notification.
It is legal for me to get but I do work in a lab. I also can’t name my sources here. It’s against the BLUA as well as professionally it wouldn’t be very wise.
Honestly and I’ve seen you mention it on down, the hepatotoxicity is very interesting to me and I thought it would be a good study for part of my PhD tbh. Not sure what angle I’ll come at it yet to be honest but...
Here is part of a paper... I’ll post the link at the bottom.
Tianeptine--an instance of drug-induced hepatotoxicity predicted by prospective experimental studies.
Abstract
We report the case of a patient who developed acute hepatitis after taking tianeptine, a new tricyclic antidepressant, for 8 weeks. Hepatitis exhibited cholangitis-like clinical features and was associated with hypersensitivity manifestations suggestive of an immuno-allergic mechanism. Histological examination showed microvesicular steatosis. The discontinuation of tianeptine administration was followed by complete recovery. Immunoallergic hepatitis and microvesicular steatosis were predicted 2 years ago from prospective experimental studies prompted by the similarity of the chemical structures of tianeptine and amineptine, another tricyclic antidepressant, well-known for its hepatotoxicity. Experimentally, tianeptine has been found to be oxidized into reactive metabolites in several rodents and human liver and to produce microvesicular steatosis probably through inhibition of mitochondrial beta-oxidation of fatty acid in mice. This case illustrates the value of prospectively assessing potential hepatotoxicity mechanisms for new compounds chemically related to drugs already known to be hepatotoxic.